礼来:记能达对早期症状性阿尔茨海默病显示出三年持续增强获益

人民财讯
Aug 02, 2025

  礼来公司公布了其TRAILBLAZER-ALZ 2三期临床研究的长期扩展(LTE)结果。数据显示,接受记能达(多奈单抗注射液)治疗的研究参与者相比阿尔茨海默病神经影像计划(ADNI)数据库中的外部未经治疗的队列,疾病进展显著减缓,且该获益在三年间持续增强。

  在研究中,较晚开始治疗的研究参与者仍然从接受记能达治疗中获益。然而,与延迟治疗组相比,早期使用记能达的研究参与者,其疾病进展至下一阶段的风险显著降低。相关数据作为重磅最新研究成果,已在于多伦多举办的2025年阿尔茨海默病协会国际会议(AAIC)上发布。

(文章来源:人民财讯)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10